Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001479290-22-000106
Filing Date
2022-12-16
Accepted
2022-12-16 16:12:11
Documents
1
Period of Report
2022-12-15

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_167122509909406.html 4  
1 FORM 4 wf-form4_167122509909406.xml 4 3584
  Complete submission text file 0001479290-22-000106.txt   4967
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Issuer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 7000 SHORELINE COURT, #371 SOUTH SAN FRANCISCO CA 94080
Business Address
Schilke Tobin (Reporting) CIK: 0001678984 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36297 | Film No.: 221468078